AstraZeneca shares fall despite Imfinzi survival-test win
AstraZeneca’s U.S. shares (AZN) fell about 0.7% to $161.51 even after Imfinzi, with Amgen’s Imdelltra, significantly extended survival among patients in a late-stage lung-cancer study.
AstraZeneca NYSE:AZN, the oncology and biopharmaceutical company, reported a late-stage lung-cancer victory Tuesday, but investors did not respond positively. S. 51 even after Imfinzi, combined with Amgen's Imdelltra, significantly extended survival among patients in the study.